PI3Kinase signaling in glioblastoma by Lino, M. & Merlo, A.
TOPIC REVIEW
PI3Kinase signaling in glioblastoma
M. M. Lino • A. Merlo
Received: 9 March 2010 / Accepted: 21 October 2010 / Published online: 10 November 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Glioblastoma (GBM) is the most common
primary tumor of the CNS in the adult. It is characterized
by exponential growth and diffuse invasiveness. Among
many different genetic alterations in GBM, e.g., mutations
of PTEN, EGFR, p16/p19 and p53 and their impact on
aberrant signaling have been thoroughly characterized. A
major barrier to develop a common therapeutic strategy is
founded on the fact that each tumor has its individual
genetic fingerprint. Nonetheless, the PI3K pathway may
represent a common therapeutic target to most GBM due to
its central position in the signaling cascade affecting pro-
liferation, apoptosis and migration. The read-out of
blocking PI3K alone or in combination with other cancer
pathways should mainly focus, besides the cytostatic
effect, on cell death induction since sublethal damage may
induce selection of more malignant clones. Targeting more
than one pathway instead of a single agent approach may
be more promising to kill GBM cells.
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Abbreviations
CNS Central nervous system
GBM Glioblastoma
PTEN Phosphatase and tensin homologue
EGFR Epidermal growth factor receptor
Moabs Monoclonal antibodies
PKI Protein kinase inhibitors
VEGF Vascular endothelial growth factor
ATM Ataxia telangectasia mutated
ATR Ataxia teleangectasia rad3 related
DNA-PK DNA-dependent serine/threonine protein
kinase
CTMB Carboxyl-terminal modulator protein
SNPs Single nucleotide polymorphism
RTEL1 Regulator of telomere elongation helicase 1
CDKN2B Cyclin-dependent kinase inhibitor 2B
MGMT O6-methyl-guanine-DNA-methyl-transferase
MMR Mismatch repair
Introduction
Gliomas, originating from the predominant glial tissue in
the CNS, are the most common primary tumors of the
central nervous system (CNS) in adults [1]. The prevalent
form is astrocytoma WHO grade IV or glioblastoma
(GBM). In affected patients, median survival is less than
1 year [2, 3]. Gliomas consist of 3 different tissue types:
astrocytomas (about 70%), oligodendrogliomas (10–30%)
and ependymomas (less that 10%). Malignant astrocytomas
include tumors of WHO grade II (low-grade malignancy),
III (anaplastic stage) and IV (highly malignant form, also
named GBM) [4]. GBM accounts for approximately 50%
of all glial tumor types. They are characterized by rapid
growth and diffuse invasiveness into the adjacent brain
parenchyma. Only the nodular component of the disease
can be controlled surgically. The infiltrative component of
the tumor, however, is left to non-specific and cytotoxic
chemo- and radiotherapy that may control tumor progres-
sion for a limited time window.
M. M. Lino (&)  A. Merlo
Laboratory of Molecular Neuro-Oncology and Departments
of Neurosurgery, University Hospitals, Hebelstrasse 20, 4031
Basel, Switzerland
e-mail: maddalena.lino@unibas.ch
123
J Neurooncol (2011) 103:417–427
DOI 10.1007/s11060-010-0442-z
Molecular genetics of GBM
The stochastic and complex process of brain tumorigenesis
involves activation of oncogenes and inactivation of tumor
suppressor genes [5–7]. A large number of genetic altera-
tions have been detected and catalogued in different brain
tumors. Familial cancer syndromes, although rare, pro-
vided a first clue to understanding the role of specific
genes, their associated pathways and to testing them in
animal models.
The most common genetic alterations detected in gliomas
are loss of heterozygosity at 10q, PTEN mutation [8], and
EGFR amplification/overexpression, along with EGFRvIII
expression [9, 10], p16/p14 co-deletion [11–13], p53 muta-
tion [14, 15], MDM2 amplification [16], loss of 1p/19q [17],
and telomerase re-activation [18]. Besides these classic
mutations, a recent comprehensive analysis was able to
confirm the known mutations and discovered still unknown
genes mutated in GBM, although at low frequency. Inter-
estingly, mutations in the active site of isocitrate dehydro-
genase 1 (IDH1) were detected in 12% of GBM patients,
mostly young patients with secondary GBMs [19].
A specific molecular signature been detected so far for
oligodendrogliomas [17, 20].
A recent paper from the TCGA (The Cancer Genome
Atlas Network) based on gene expression-based molecular
classification subdivides GBM into Classical, Mesenchy-
mal and Proneural subtype. Each group shows a different
aberration and gene expression, which may predict therapy
efficacy. The Proneural subtype was associated with
younger age, PDGFRA abnormalities, IDH1 and TP53
mutation and resistance to temozolomide and radiation
therapy. The Classical GBM with EGFR abnormalities
showed the best reaction to therapy, while the mesenchy-
mal subtype, characterized by high expression of CHI3L1
and MET and NF1 mutation/deletion, reported only a
partial response to treatment [21].
Recently, it was shown that high-grade glioma risk is
associated with inherited variation in a region of 9p21
containing CDKN2B and a region of 20q13.3 tagged by
two intronic SNPs in RTEL1 [22].
MGMT, a DNA repair enzyme, is associated with glio-
blastoma sensitivity to alkylating agents. Two different
groups reported that patients with glioblastoma containing a
methylated MGMT promoter benefited from temozolomide,
in comparison with patients that did not have a methylated
MGMT promoter [23–25]. Methylation of MGMT promoter
has been proved to be an independent and stronger prog-
nostic factor, better than age, stage and tumor grade, and
predicting responsiveness of glioma to alkylating agents.
The TCGA group found that the mutational spectra in the
MMR genes paralleled MGMT methylation status and
treatment consequences. MMR deficiency and MGMT
methylation together may therefore influence the overall
frequency and pattern of somatic point mutations in glio-
blastoma tumors [26].
Even though GBM share many of these alterations, each
individual tumor has its own unique pattern of genetic
changes that represents a considerable barrier to the devel-
opment of therapeutic intervention [27]. The putative
Achilles heel of GBM may not be a single major genetic
alteration, but rather a secondary acquired imbalance in the
aberrant signaling network that impinges on essential reg-
ulatory pathways.
In this review, we will describe the PI3Kinase network
and its role in GBM.
EGFR and GBM
EGFR is the first member of the ErbB (Her) family of
RTKs. The two main EGFR ligands are EGF and TGF-a
(transforming growth factor-a), among other ligands like
beta-cellulin, epiregulin, heparin binding EGF (HB-EGF),
and amphiregulin. Ligand binding to EGFR induces
receptor phosphorylation, which in turn activates a complex
downstream signaling network [28]. Downstream signaling
through PI3K-PKB [20], PI3K-Rac-Rho, Ras-Raf-Mek-Erk
and Jak-STAT influence proliferation [29], migration [30],
invasion, resistance to apoptosis [31, 32], and tumor neo-
vascularization [33, 34] (Fig. 1). Overexpression of EGFR
has been found in many different tumor types including
GBM, and has been consistently found to be correlated with
a poor outcome [12, 35]. Genetic alterations like overex-
pression, small deletions or mutations can lead to oncogenic
upregulation of the receptor [36]. In GBM, activation of
EGFR is present in 40–60% of tumors [37]. The most fre-
quent activating mutation is the EGF mutant receptor vIII
(EGFRvIII) [36]. Amplification of EGFR gene in GBM
leads to downstream activation of PI3K/PKB/mTOR/rpS6.
Interestingly, it has been shown that inhibition of EGFR
signaling correlates with decrease p-mTOR and p-rpS6 in
cells wild-type for PTEN. In contrast, inhibition of EGFR
signaling fails to affect p-mTOR or p-rpS6 in cells mutant
for PTEN. Recently, a PKB independent pathway linking
EGFR to mTOR through PKC (protein kinase C) was
described indicating an additional drug target [38].
The role of PI3Kinase in the glioma signaling network
Members of the phosphatidylinositol 3-kinase (PI3K) family
are lipid kinases involved in diverse signaling pathways that
regulate proliferation, differentiation, migration, trafficking,
and glucose homeostasis [39–42]. They contain a p110
catalytic subunit that heterodimerizes with five distinct
regulatory subunits (p85a, p55a, p50a, p85b, and p55c). The
p110 catalytic subunit includes an N-terminal p85 binding
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domain, a Ras binding domain, a C2 domain, a phosphati-
dylinositol kinase homology (PIK) domain, and a C-termi-
nal catalytic domain. The PIK and catalytic domains of p110
are homologous to other protein kinase domains including
mTOR, ATM (ataxia telangectasia mutated), ATR (ataxia
teleangectasia rad3 related) and DNA-PK (DNA-dependent
serine/threonine protein kinase). Mutations within the p110
subunit of PI3K, that are mainly gain of function mutations,
have been identified mostly in exon 9 (helical domain) and in
exon 20 (kinase domain) [43, 44]. In mammals, 8 distinct
PI3K have so far been described. They are divided into
classes I–III according to their substrate specificity, regu-
lation and structure. Class I PI3Ks contain two subgroups,
IA (p110a, p110b and p110d) and IB (p110c), which are
activated by growth factor receptor tyrosine kinase (RTKs)
and by G-protein-coupled receptors (GPCRs), respectively
[42]. Class II PI3Ks consist of a single p110-like catalytic
subunit that regulates membrane trafficking and receptor
internalization [41, 45]. Class III PI3Ks has been found to
regulate mTOR activity in response to availability of amino
acids for the control cell growth [46–48].
PI3K are activated by a wide range of upstream signals
and phosphorylate the lipid phosphatidylinositol-4,5,-
bisphosphate, generating phosphatidylinositol-3,4,5-tris-
phosphate (PIP3) [41, 42]. The protein serine/threonine
kinase PKB (also known as AKT) is the principal PIP3
target. PKB is recruited to the membrane upon binding of
PIP3 with subsequent phosphorylation by the mTOR-rictor
kinase complex and by PDK1 (3-phosphoinositide-depen-
dent kinase). Activation of PKB, in turn, phosphorylates
many target proteins which regulate cell metabolism, cell
cycle and cell survival [49, 50], protein synthesis [47], cell
polarity, cell motility [51], and vesicle sorting [52] (Fig. 1).
Therefore, the signaling components PI3K/PKB/mTOR
are central regulators of cell proliferation, growth, differ-
entiation, and survival. Moreover, PI3K regulates migra-
tion and invasion, mainly by the Rho family members
Cdc42, Rac and Rho [53, 54]. These small GTPases
dynamically remodel the actin cytoskeleton and give rise to
filopodia, lamellipodia and stress fibers [55, 56].
PI3K dysregulation is observed in a variety of tumors
[44, 57–60] including GBM [44, 59], but also in other non-
neoplastic human disorders [61]. For example, attenuated
PI3K signaling downstream of the insulin receptor signif-
icantly contributes to the type-2 diabetes phenotype [62]. In
human cancers, p110 of PI3K is frequently amplified [44].
This observation has been confirmed by another study that
described PI3K p110 mutations in 15% of glioma samples,
and 21% in pediatric and 17% in adult brain tumor samples
[63]. In addition, elements of the PI3K signaling pathway
are also frequently mutated, such as PTEN [64, 65] and the
carboxyl-terminal modulator protein (CTMB) [66, 67].
Transgenic and knockout mouse models have confirmed
the role of the PI3K-PBK pathway in tumorigenesis [68].
The TCGA group reported novel in frame deletions in the
adaptor domain of PIK3CA. Interestingly in PI3KCA wild-
type patients were found mutation in PIK3R1. These
mutations clustered always around amino acid residues that
disrupt C2-iSH2 interaction reducing the inhibitory effect
of p85a on p110a [26].
Fig. 1 The PI3K pathway
activates different processes that
regulate proliferation, apoptosis
and migration. Schematic
representation of the signaling
pathway activated by receptor
tyrosine kinase (RTK) and the
PI3K downstream activation.
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PTEN (Phosphatase and tensin homologue) tumor sup-
pressor gene encodes a phosphatase that catalyzes the
dephosphorylation of phosphatidylinositol 3,4,5 triphos-
phate (PIP3), negatively regulating the activity of PI3K [8].
The PI3K/PTEN/PKB-pathway is of critical importance for
angiogenesis, cell proliferation and survival [31, 50].
Homozygous Pten-knockout mice are embryonically lethal
while heterozygous animals are viable but develop various
tumors [69]. Loss of function mutations of PTEN are fre-
quent in GBM and activate PKB in a similar way as
mutations in PIK3CA [70]. Epigenetic gene silencing by
promoter methylation also inactivates PTEN [71]. In ani-
mal models, haploinsufficiency was sufficient to promote
tumorigenesis for certain tumor types, and progressive
reduction of PTEN resulted in increasingly aggressive
tumors [72, 73]. Transfection of PTEN resulted in reduced
proliferation and induction of cell cycle arrest at G0/G1,
accompanied by inactivation of PKB phosphorylation at
Ser-473 [74]. In addition, exogenous PTEN expression
induces astrocytic differentiation in the presence of the
ECM [74] while neural stem cells self-renewal is nega-
tively regulated by modulating GO-G1 cell cycle entry
[75, 76]. PTEN expression sensitizes GBM cells to radia-
tion, but not to chemotherapeutic drugs [77]. Epigenetic
and genetic inactivation of PTEN is associated with shorter
survival in GBM patients [8, 12, 78, 79].
PI3Kinase mouse model
P85b knockout mice develop hypoinsulinemia and hypo-
glycemia [80, 81]. Loss of all isoforms of PIK3R1
(including p50a and p55 a) resulted in perinatal lethality
and caused a decrease in the expression and activity of
class IA PI3K catalytic subunits. Heterozygous disruption
of PIK3R1 improved insulin signaling and glucose
homeostasis [82].
Mice carrying homozygous deletions for either p110a or
p110b were found to be embryonic lethal [83, 84]. Inhib-
itors of p110a blocked insulin-stimulated phosphorylation
of PKB, while inhibitors of p110b had no effect on insulin-
stimulated phosphorylation. These results suggested that
p110a has a key role in the PI3K-dependent insulin sig-
naling [62]. Direct tumorigenic effect was proved in con-
ditional and prostate-specific PTEN mutation: ablation of
p110 blocked PTEN-/--induced tumor formation [85].
Disease targets and ligands
Glioblastomas may develop de novo (primary GBMs) or
through progression from low grade to high-grade astro-
cytomas (secondary GBMs) [27]. Radiotherapy has been
shown to prolong the median survival of GBM patients
[86] and is the standard adjuvant therapy for high-grade
GBM, nowadays often combined with the radiosensitizer
temozolomide [87]. However, GBM can relapse close to
the targeted resection margins or within 2 cm of the
resection cavity. Other therapies such as seed-based
brachytherapy [88] or radiosurgery have limited additional
therapeutic value. Novel loco-regional treatments using
peptide-toxin- or radiolabeled peptide-conjugates are being
evaluated [89].
To substantially improve prognosis, more specific ther-
apies are being developed against a number of new critical
molecular targets: growth factor receptor inhibitors (gefi-
tinib and erlotinib) [90–92], matrix metalloproteinase
inhibitors (marimastat, metastat and prinimastat) [93] and
blockers of angiogenesis [94–98]. We will now focus on
the role of PI3K in GBM, discuss the effects of PI3K
inhibitors on glioma cell survival and proliferation, and
perspectives of upstream and downstream interference.
Targeting PI3K and downstream pathway in GBM
Different RTK inhibitors have been developed and studied
in different cancer types including GBM, targeting EGFR,
PI3K, mTOR and PKB.
Targeting EGFR
Two different types of EGFR inhibitors have been devel-
oped: monoclonal antibodies (MoAbs) and small molecule
inhibitors of EGFR tyrosine kinase activity, competing for
the ATP binding site. The mechanism of receptor inhibition
differs between the two types of drugs. MoAbs interfere
with EGFR activation by blocking the extracellular ligand-
binding domain. Protein kinase inhibitors (PKI) block the
intracellular tyrosine kinase-mediated signaling pathways.
Many different MoAbs have been developed with different
affinity, specificity and negative regulatory effect. Cetux-
imab (IMC-225, ErbituxTM; ImClone systems, Princeton,
NJ, USA), a MoAb which binds EGFR with higher affinity
than the natural ligands, has fairly recently been FDA-
approved for treatment of patients with EGFR-positive
metastatic colorectal cancer, and since December 2005 by
Swissmedic for the treatment of patients with squamous
cell carcinoma of the head and neck in combination with
radiotherapy. Regarding GBM, the hR3 (TheraCIM;
CIMYM Biosciences, ON, Canada), a human high affinity
MoAb to EGFR that is now in phase I/II clinical trial
(NCT00369252), has shown a partial response in a GBM
study. The use of mAb 806 (Ludwig Institute, Victoria,
Australia) that targets mutant EGFRvIII on glioma cell
lines and mouse xenografts overexpressing EGFRvIII led
to a dose-dependent growth inhibition [99]. Mab-806 is
now in preclinical trial in an orthotopic murine glioma
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model, using EGFRvIII-positive U87MG cells [100].
Moreover, a combinatorial study, which uses mAb 806 and
mAb 528, showed additive antitumor activity in human
tumor xenografts [99]. The use of Cetuximab in tumor cell
lines and a xenograft model induces apoptosis and inhibits
angiogenesis [101, 102]. The small molecule inhibitors of
EGFR are less specific than the MoAb and therefore the
clinical effect was found to be less predictable. Neverthe-
less, these drugs have a low molecular weight, allowing
better tumor penetration and can be administered orally.
Gefitinib (ZD1839; AstraZeneca, Wilmington, DE, USA)
and Erlotinib (OSI-774, CP-358, 774, Tarceva; OSI Phar-
maceuticals, in collaboration with Genentech and Roche
Pharmaceuticals) have been FDA-approved for different
cancer types and new clinical trials in GBM patients are
ongoing. Gefitinib showed only a limited activity in GBM
patients [103] and colorectal cancer [104]. It did not
improve survival as mono-therapy in patients with non-
small cell lung cancer stage III nor when following
chemotherapy and radiation therapy [105]. AEE-788
(LymphoSign), a potent EGFR and VEGF2 inhibitor, is
currently in Phase I clinical trial (NCT00116376) for
GBM. Erlotinib appears to be more effective against
malignant glioma than gefinitib when comparing the
radiographic response rate, but none of them have a clear
impact on survival.
The limited effect of these PKI against EGFR raised the
question whether drug efficiency could not be improved by
a combinatorial strategy. In a pre-clinical GBM cell line
model blocking EGFR activity with the protein kinase
inhibitory drug AEE788, we found a 10–20% reduction of
cell proliferation but only a limited pro-apoptotic effect in
the minority of GBM cell lines [106]. Gleevec (PKI of the
PDGF receptor developed by Novartis) that inhibits Bcr-
Abl and also has an activity against PDGFR and c-kit
combined with AEE788 (Novartis) and RAD001 (an ana-
log of rapamycin that inhibits mTOR developed by
Novartis) was only marginally effective. However, the
combination of AEE788 and patupilone (a cell cycle
inhibitor blocking polymerization of microtubuli, devel-
oped by Novartis) synergistically induced apoptosis in 50%
of GBM cell lines [106]. A synergistic effect was also
found when combining erlotinib with the PI-103 that led to
an increased proliferation block when compared with
monotherapy or a combination of erlotinib and rapamycin.
Such combinations may be effective against EGFR-driven
PTEN mutant tumors [107]. EGFRvIII expression in GBM
promotes DNA-PKcs (DNA dependent protein kinas cata-
lytic subunit) and DBS (DNA double-strand breaks) repair
most probably through the augmented PI3K/Akt1 signal-
ing. This mechanism suggests that blocking the DBS and
DNA-PKcs pathway together with an EGFR inhibition
could lead to better results [108]. Using the EGFR inhibitor
gefinitib together with an HMG-CoA reductase induces
another interesting synergism, irrespective of EGFRvIII
and PTEN status [109].
PI3K inhibitors
Several compounds inhibiting PI3K have been developed,
e.g., wortmannin [110], Ly294002, staurosporine, quercetin,
demethoxyviridin and PI-103 among others. Wortmannin
and demethoxyviridin are potent, irreversible, but non-
selective inhibitors of all PI3K. LY-294002 and quercetin
are reversible and potent PI3K inhibitors, but non-selective
and also bind other members of the PI3K family [111]. Most
protein kinase inhibitors block access of ATP to the ATP-
binding pocket by distinct stoichiometric interactions [112].
Wortmannin has shown activity against tumor xenografts
from melanoma [113], breast [114], colon [114], ovarian
[114], and pancreatic cancer [115]. Treating EGFRvIII gli-
oma cell lines with wortmannin significantly suppressed cell
growth to a similar extent as EGFR inhibitors [116]. Wort-
mannin has also been shown to be an effective radiosensi-
tizer of glioma cells [117], and displayed, when tested on a
panel of GBM cell lines, a slight pro-apoptotic effect [106].
LY-294002 efficacy has been studied in glioma cell lines. It
significantly reduced the level of PtdIns (3,4,5)P3, inacti-
vated phospho-PKB, and blocked cell proliferation in a
dose-dependent manner [118]. Moreover, Ly294002 blocks
p53 induction by inhibiting stabilization of p53. Neverthe-
less, this down-regulatory effect on p53 by PI3K inhibitors
(attenuating p53-dependent cell death) [119] may not be so
relevant for many cancers, since the p53 pathway is inacti-
vated in most cancers.
A new series of PI3K inhibitors, which selectively target
different PI3K isoforms, were synthesized. The small
molecule inhibitor PI-103 showed unique activity against
genetically different GBM cell lines. PI-103 selectively
blocked p110a and mTOR complex at nanomolar con-
centration [120]. Only down-regulation of p110a specifi-
cally blocked glioma proliferation in vitro, but not p110b
[120]. PI-103 was efficient, irrespective of the genetic
status of cell lines (PTEN, p53 and EGFR). In vivo data
show that PI-103 was effective and non-toxic in glioma
xenograft models [120, 121]. Since mTOR inhibition may
lead to PI3K activation, theoretically, blocking mTOR
combined with a PI3K inhibitor may induce cell death.
PI3K inhibitors like Ly294002 enhance apoptosis triggered
by TRAIL or cytotoxics (vincristine, doxorubicine, etopo-
side, etc.) [122]. Recently, an interesting paper showed that
HOXA9 transcription was activated in GBM leading to
decreased apoptosis and increased proliferation. Tran-
scriptional activation of HOXA cluster was blocked by
PI3K inhibitor through an epigenetic mechanism involving
histone H3k27 tri-methylation [123].
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PI3K downstream inhibition
PKB inhibition
The serine/threonine kinase PKB is one of the enzymes
regulated by PI3K activity by regulating PtdIns-3,4,5-P3
levels. Its activated form down-regulates Bad, caspase-9,
GSK-3beta and forkhead transcription factors, suppressing
apoptosis and promoting cell survival [31, 124]. In addi-
tion, PKB increased levels of vascular endothelial growth
factor (VEGF) under hypoxic conditions [125]. PKB is
activated in about 80% of GBM [126]. Activated PKB
together with mutant Ras was found to be tumorigenic in a
murine glioma model [68]. In another model using astro-
cytes expressing E6/E7, hTERT (human telomerase reverse
transcriptase) and Ras, upgrading of a low-grade to a high-
grade tumor was achieved by addition of activated PKB
[127]. The effect of PKB in the regulation of cell cycle,
apoptosis and angiogenesis of GBM cell lines strongly
suggests a role in the development of GBM. The two PKB
inhibitors, KP-372-1 and KP-37-2, induced apoptosis in
GBM cells [128].
mTOR inhibition
The TOR family of proteins has multiple functions: regu-
lation of mRNA transcription and translation in response to
essential nutrients, membrane trafficking, protein degrada-
tion, organization of the actin cytoskeleton, and PKC
signaling [129, 130]. There is a rapamycin-sensitive mTOR-
complex (mTORC1) and a rapamycin-insensitive complex
(mTORC2). mTOR activates S6K1 and EBP1. mTOR can
also be up-regulated indirectly through activation of PI3K
and PKB. Different mTOR inhibitors have been developed
and are being assessed in clinical trials: the rapamycin
prototype and three rapamycin derivatives RAD001 (ever-
olimus), CCI-779 (temsirolimus), and AP23573. All mTOR
inhibitors form a complex with the intracellular immuno-
philin FKBP12 and inhibit mTOR. The wide spectrum of
rapamycin covers infectious, immunosuppressive, endo-
thelial and neurodegenerative disease.
Rapamycin has been shown to have a growth inhibitory
effect in several human and murine cancer cell lines both in
vitro and in a xenograft model [131–134]. Rapamycin
induces a decrease in cyclin D1 expression and an increase
in p27 levels, leading to a cell cycle block in late G1/S-
phase [135]. Rapamycin has also been shown to induce cell
death in a limited number of tumor models, although the
molecular mechanism leading to apoptosis is not clear. One
of the mechanisms may be that the downstream target of
mTOR—S6K1—inactivates the pro-apoptotic molecule
BAD [136, 137]. Recently, it has been shown that inhibi-
tion of mTOR/S6K1 triggers a negative feedback loop
resulting in the activation of AKT signaling probably
through a IGF-1R-dependent mechanism. Inhibiting mTOR
also has an effect on the angiogenesis by blocking the
translation of HIF-a [138]. Anti-angiogenic effects on
endothelial cells have further been shown in a rapamycin-
sensitive murine tumor model [139]. An interesting paper
from Liu et al. showed that NVP-BEZ235, a novel dual
PI3K/mammalian target of rapamycin (mTOR) inhibitor,
was able to inhibit PI3K and mTOR signaling,and induce
cell cycle arrest, down-regulation of VEGF and autophagy
in gliomas [140]. Different studies combining mTOR
inhibitors together with other anti-cancer compounds have
been published with contradictory findings [106, 141, 142];
however, in vitro results may not predict clinical efficacy
given the wide spectrum of rapamycin effects. Different
clinical trials are now being performed for the rapamycin
derivates CCI-779 (http://clinicaltrials.gov/ct2/results?term
=CCI-779), RAD001 (http://clinicaltrials.gov/ct2/results?
term=RAD001) and AP23573 (http://clinicaltrials.gov/ct2/
results?term=AP23573) alone or in combination with other
drugs. The most promising results have been described for
renal cell carcinoma [143], endometrial cancer [144], and
mantle cell lymphoma [145], but also giant cell astrocy-
toma in tuberous sclerosis patients. Phase II studies have
been performed in recurrent GBM patients, with limited
anti-tumor activity [146, 147]. Given the negative feedback
loop between mTOR and PKB via IGF-1R, an mTOR
inhibitor combined with an IGF-1R antibody/inhibitor may
be a promising strategy to increase therapeutic efficacy
[148].
Drug combinations
Use of drug combinations is of particular interest, given the
limited responses obtained in clinical trials using single
drug approaches. In cases of an additive or synergistic
effect, drug doses of each respective compound can be
reduced, potentially paralleled by a reduction in side
effects. We studied the impact of different drug combina-
tions on survival and proliferation of GBM cell lines.
Targeting EGFR with AEE788 and PDGFR with Gleevec
and/or mTOR with RAD001, we found that single and
combined applications did not significantly enhance back-
ground apoptosis rates [106]. However, the combination of
AEE788 with the microtubuli inhibitor patupilone induced
apoptosis in some 50% of cell lines, which was accompa-
nied by simultaneous inactivation of both p-ERK and
p-PKB. Asking whether down-regulation of p-ERK and
p-PKB is critical for GBM cell survival, we directly
blocked the PI3K/PKB and Ras/Raf/MEK/ERK pathways
with both the PI3K inhibitor wortmannin and the MEK
inhibitor UO126. This combination frequently killed GBM
cells, supporting a model of an additive effect by targeting
422 J Neurooncol (2011) 103:417–427
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these two signaling pathways that results in a reduced
threshold for the induction of apoptosis. We did not find
any correlation between the sensitivity or resistance of
GBM cells to apoptosis and their genetic status [106].
Simultaneous treatment with rapamycin and the EGFR
inhibitor (EKI-785) resulted in synergistic anti-prolifera-
tive and pro-apoptotic effects [149]. At a molecular level,
rapamycin alone decreased S6 phosphorylation, while
EGFR inhibitor reduced phosphorylation of STAT3 (signal
transducer and activator of transcription). Rapamycin alone
increased phosphorylation of PKB and promoted the
binding of the translational inhibitor eukaryotic initiation
factor 4 binding protein (4EBP1) to the eukaryotic trans-
lational initiation factor 4E (eIF4E), which are blocked by
EGFR inhibition [150]. Simultaneous blocking of multiple
enzyme activities may reduce the effect of compensatory
signaling which is one of the therapeutic limitations of
using single agent therapy. However, suppressing cross-
talk may not be accompanied by an enhanced therapeutic
effect. Furthermore, combining the anti-malaria drug ar-
tesunate (ART) with the EGFR inhibitor OSI-774 resulted
in an in vitro cytostatic effect which was most pronounced
in a background of constitutively active EGFR [151].
Results of a Phase II study of Imatinib mesylate (Gleevec)
plus hydroxyurea showed that this combination was well
tolerated and associated with a modest clinical response in
a subgroup of patients with recurrent GBM [91]. PI3K
inhibitor (as LY294002 and wormannin) sensitizes GBM
cells to apoptosis. This mechanism act both activating
extrinsic apoptosis through TRAIL (tumor necrosis factor-
related apoptosis-inducing ligand) and CD95 and the
intrinsic mitochondrial apoptotic pathway [152].
Conclusions
The promise of Gleevec—the concept that each cancer may
have its unique molecular signature that can be therapeu-
tically exploited—has not yet been met. In GBM, there are
a large number of different molecular targets, and the net
effect on signaling by individual mutational patterns may
also be unique for each tumor. Nonetheless, empirical drug
combinations showed improved therapeutic effects over
single agent approaches. A fundamental question is whe-
ther GBM have an Achilles heel or whether each tumor
requires its individual drug combination. Components of
the MAPK pathway, such as Raf [153] and MEK [106],
displayed empirical evidence of efficacy when combined
with drugs that target PKB/Akt [61] and mTOR [150].
Sublethal damage will select more malignant clones, con-
sidering the high degree of genetic instability of malignant
human tumors [154]. Hence, therapeutic interference must
aim at induction of tumor cell apoptosis. An interesting
approach is to use drugs that exploit a general mechanism
respecting individual patterns of alterations, e.g., epige-
netic signatures of gene expression. For example, histone
deacetylase inhibitory drugs induce re-expression of
silenced genes in an unpredictable individual way, mim-
icking the stochastic nature of the disease [155]. Experi-
mentally, HDAC inhibitory drugs displayed a remarkable
pro-apoptotic effect upon combination with agents that
block glucose utilization, such as 2-deoxy-glucose [156].
Combining new classes of cancer drugs with anti-meta-
bolic strategies may lead to innovative new concepts to
attack this disease, leading to enduring clinical responses
by successful control of tumor cell proliferation, survival
and invasion.
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